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ABSTRACT
Objective To determine whether early initiated anti-
inflammatory therapy with prolonged high dose inhaled
glucocorticoids influences the occurrence and severity of
recurrent wheeze after respiratory syncytial virus related
lower respiratory tract infections.
DesignRandomiseddoubleblindplacebocontrolledtrial.
Setting Paediatric departments of 19 Dutch clinical
centres.
Participants 243 previously healthy infants (126 boys,
117 girls) aged less than 13 months and admitted to
hospital with respiratory syncytial virus infection.
Interventions 200 μg extra fine hydrofluoroalkane (HFA)
beclometasone dipropionate twice daily or matched
placebo administered by a pressurised metered dose
inhaler and a spacer during the first three months after
hospital admission.
Main outcome measure The primary outcome was the
number of days with wheeze in the year after the three
month intervention period.
Results Of the 243 eligible infants, 119 were randomised
to receivebeclometasoneand124to receiveplacebo. No
significant difference was found in the number of days
with wheeze between the two groups (total days, 1761/
33568 in the beclometasone group v 2301/36556 in the
placebogroup,P=0.31)andtheproportionofinfantswith
wheeze did not differ between the groups (61% in the
beclometasone group v 62% in the placebo group,
P=0.90).Inthepredefinedsubgroupofinfantswhodidnot
need mechanical ventilation (n=221), beclometasone
reducedthenumberofdayswithwheezeby32%(relative
reduction in total days, 1315/30405 in the
beclometasone group v 2120/33149 in the placebo
group, P=0.046). This reduction was most pronounced
during the first six months of the follow-up year after
intervention.Theproportionofinfantswithwheezedidnot
differ between the groups (59% in the beclometasone
group v 60% in the placebo group, P=0.89).
Conclusions Early initiated high dose extra fine HFA
beclometasone to infants during the first three months
after hospital admission for respiratory syncytial virus
infection has no major effect on recurrent wheeze. The
general use of such treatment during lower respiratory
tract infection with respiratory syncytial virus should not
be advocated.
Trial registration Current Controlled Trials
ISRCTN12352714.
INTRODUCTION
Respiratory syncytial virus related lower respiratory
tract infection is the most common cause of infants
being admitted to hospital during winter and is often
followed by recurrent transient episodes of wheeze.
1-3
Recurrent wheeze after respiratory syncytial virus
infection has a high prevalence,
4 influences quality of
life,
5 and generates substantial healthcare costs.
6
It has been hypothesised that the infection and
concomitant inflammatory reaction in the acute phase
of the infection leads to recurrent wheeze.
7 In line with
this hypothesis, immune modulation during the acute
phasemightinfluencerecurrentwheeze.Evidenceonthe
effectiveness of early anti-inflammatory therapy in the
prevention of recurrent wheeze is conflicting,
8-10 and the
use of inhaled glucocorticoids varies greatly among
countries.
11-15ThirtypercentofpaediatriciansinSwitzer-
land reported that they always start inhaled glucocorti-
coids in patients admitted to hospital with respiratory
syncytial virus related lower respiratory tract infection
whereas 11% of paediatricians in Ireland selected such
treatment in the case of a three month old infant with
moderately severe disease.
1415 No large trials have
studied the effect of inhaled glucocorticoids on recurrent
wheeze after respiratory syncytial virus infection,
16
preventing strong recommendations on the use of
inhaled glucocorticoids. We carried out a large rando-
miseddoubleblindplacebocontrolledtrialtoinvestigate
whether early initiated high dose extra fine hydrofluor-
oalkane (HFA) beclometasone diproprionate for three
months after admission to hospital for respiratory
syncytial virus infection prevents recurrent wheeze.
METHODS
The RSV Corticosteroid Study is a multicentre,
randomised double blind placebo controlled trial
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beclometasone with placebo in infants aged less than
13 months admitted to hospital for lower respiratory
tractinfectionandwithapositiveimmunofluorescence
result for respiratory syncytial infection in epithelial
cells from nasopharyngeal aspirates. We excluded
infants who had previously been given steroids, had a
history of cardiac or pulmonary disease, or had had a
previous illness with wheeze. Recruitment took place
during the winter seasons from November 2004 to
February 2006 in the paediatric departments of 19
clinical centres in the Netherlands. Written informed
consent was obtained from the infants’ parents. Good
clinical practice guidelines were followed.
Randomisation
Eligible infants were randomly assigned to receive
either extra fine HFA beclometasone dipropionate or
placebo. Randomisation was by means of a computer
generated list of six numbers in each block and fixed
blocks within each hospital. Local investigators at the
paediatric departments enrolled infants and provided
boxescontainingtheallocatedtreatment.Blindingwas
achievedbyusingactiveandplacebodrugsofidentical
shape and taste. The doctors, nurses, parents, and
investigatorswereunawareoftherandomisationcodes
until data entry was complete.
Study intervention
Interventions were 200 μg extra fine HFA beclometa-
sonedipropionate(Qvar; 3M,TevaPharma,Haarlem,
theNetherlands)twicedailyormatchingplacebogiven
by pressurised metered dose inhalers and a spacer
(Aerochamber;TrudellInternationalEurope,Notting-
ham). The extra fine beclometasone formulation has
smaller particles than conventional inhaled glucocor-
tiocosteroids and is possibly more effective.
17 Treat-
ment was started within 24 hours of respiratory
syncytial virus being detected and continued for three
months. Treatment in infants with severe disease who
needed mechanical ventilation was started within 24
hoursofextubation.Asthmanursestaughtthepatients’
parents correct inhaler techniques. Parental compe-
tence was evaluated three weeks after hospital dis-
charge in 177 infants. Performance was scored on six
items according to modified criteria of the Dutch
Asthma Foundation
18 (shaking of the inhaler, correct
assembly of spacer and canister, activation of the
canister, no more than three puffs at the same time,
inhalation during at least 10 seconds, moving spacer
valve). Median scores for performance in both groups
were 6 (interquartile range 5-6).
Infants were followed up for one year after
completion of treatment, during which time we
determined the number of days with wheeze (the
primary outcome measure). At the discretion of the
paediatricians at the clinical centres, open label
bronchodilators could be added to the study treat-
ment if required. If steroid therapy was necessary,
study treatment was discontinued.
Primary and secondary outcome measures
Parents recorded airway symptoms and the use of
airway drugs in a daily log.
19 The logs were kept for
15 months from the start of intervention. They were
returned to the investigators every three months.
Parents were instructed how to complete the logs by a
single investigator and telephone calls were scheduled
every three months for motivational purposes.
The primary outcome was the number of days with
wheeze.Secondaryoutcomeswerethenumberofdays
with cough, the number of days using airway drugs,
duration of hospital stay, health related quality of life,
lungfunction,potentialadverseeffectsoftreatmenton
growth, and incidence of thrush. We assessed health
related quality of life with the TNO-AZL preschool
children quality of life questionnaire
20 during the
winter season one year after admission to hospital.
Theinfantsweretestedforlungfunctionandbronchial
responsivenessatage2yearsbymeasuringinterrupter
resistance using a transducer (MicroRint; Micro
Medical, Rochester, Kent). The interrupter technique
measures changes in mouth pressure after a brief
interruption of airflow at the mouth. It is based on the
principlethatthealveolarpressureandmouthpressure
equilibrate within a few milliseconds of brief inter-
ruption of airflow. Airway resistance can be calculated
fromtheratioofmouthpressuretoairflowatthemouth
just before occlusion,
21 and this was measured before
and after administration of 400 μg of inhaled salbuta-
mol using a spacer. Growth was evaluated by measur-
ing height at age 2 years.
To obtain data on respiratory symptoms, allergy,
parental smoking, and allergy symptoms among first
degree family members we used an extended Dutch
versionofthestandardisedquestionnaireoftheBritish
MedicalResearchCouncilandtheDutchversionofthe
European community respiratory health survey
questionnaire.
2223
Statistical analysis
The sample size was based on prevalence data for the
primary outcome obtained from our previous follow-
up study on respiratory syncytial virus bronchiolitis.
19
Inthatcohort,80%ofinfantswheezedatanytime,with
Infants randomised (n=243)
Assigned to
beclometasone (n=119)
Assigned to
placebo (n=124)
Included in intention to
treat analysis (n=119)
Included in intention to
treat analysis (n=124)
Excluded (n=7):
  Thrush (n=2)
  Discomfort or problems with
    compliance (n=5)
Excluded (n=9):
  Started steroid treatment
    (n=4)
  Discomfort or problems with
    compliance (n=5)
Fig 1 | Flow of patients through study
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15 months after infection of 34.2 (95% confidence
interval26.2to42.3days).Thepredefinedtargetof250
patients provided at least 90% power to detect a
clinically relevant difference of 14 days with wheeze
between both arms.
We analysed the effects of beclometasone on the
occurrence of any wheeze, cough, use of airway drugs,
and thrush during follow-up. Percentages and asso-
ciated 95% confidence intervals of infants with any
symptomswerecalculated.Wecountedthenumberof
days with symptoms or drug use, or both, to evaluate
theeffectoftreatmentontheseverityofwheeze,cough,
and drug use. As a typical Poisson distribution for
probability arose we used Poisson regression analysis
to study potential differences in number of days with
wheeze and cough and in days of airway drug use.
Duration of hospital stay (days), quality of life domain
scores, measurements of interrupter resistance (kPA/
L/s), and height (cm) are expressed as medians and
means. We used χ
2 tests, Student’s t tests, and Mann
Whitney U test to evaluate differences in percentages,
mean values, and median values between the groups.
To detect possible effect modification we carried out
two prespecified subgroup analyses—the need for
mechanical ventilation (yes v no) and the presence of
signsindicatingairflowlimitationduringinitialrespira-
torysyncytialvirusinfection—thatis,doctordiagnosed
wheeze by auscultation (yes v no).
24
To decrease bias and increase statistical efficiency,
we imputed missing data for quality of life domain
scores, interrupter resistance measurements, duration
of hospital stay, height, and presence of thrush.
Imputation was done using the linear regression
method (missing value analyses) available in SPSS for
Windowsversion13.0software.
2526Suchimputationis
based on the correlation between each variable with
missingvaluesandallothervariablesasestimatedfrom
the full dataset of participants with complete data. All
analyses were done on an intention to treat basis,
implying that no adjustments were made for the need
forsteroidtreatmentduringtheinterventionperiod.In
addition we carried out analyses on infants with
complete log data (complete case analyses).
RESULTS
A total of 323 parents were asked if their child could
participateinthisinterventionstudy;78wereexcluded
for various reasons (previous use of steroids, cardiac
history, not willing to participate). Overall, 243 infants
were randomised: 119 to extra fine HFA beclometa-
sone and 124 to placebo (fig 1). Table 1 shows the
baselinecharacteristicsofbothgroups.Duringtheyear
of observation airway symptoms were recorded for
2305 months (79% of total months). The median
duration of follow-up for both groups was 15 months
(interquartile range 12-15 months).
Airway symptoms and use of drugs during observation
year
Table 2showsthenumberofdayswithsymptomsand
thenumberofdaysusingairwaydrugsduringthe year
of observation. During the entire year of observation
the number of days with wheeze in the total group and
in the predefined subgroup of infants with signs of
airway limitation during infection was similar but was
lowerin thesubgroupofnon-ventilatedinfantstreated
withbeclometasone(n=221).An absolutereductionin
days with wheeze of 2.1% was observed (total days,
2120/33149(6.4%)intheplacebogroupv1315/30405
(4.3%)inthebeclometasonegroup,P=0.046),arelative
reduction of 32%. Infants treated with beclometasone
also had fewer days with cough. No other differences
wereobserved.Resultsweresimilarwithcompletecase
analyses.
Figure 2 shows the distribution of days with wheeze
during follow-up in the two treatment groups. To gain
insight into the short term effects of intervention,
Poisson analyses were carried out separately for the
firstsix monthsof the observationyear andthe second
six months. These retrospective Poisson analyses
showed a more pronounced reduction in the number
of days with wheeze during the first six months than
during the second six months in the total group (total
days, 1354/19048 (7.1%) in the placebo group v 949/
17664(5.4%)inthebeclometasonegroup,P=0.18)and
in the subgroup of non-ventilated infants (total days,
1265/17215 (7.3%) in the placebo group v 683/16043
(4.3%) in the beclometasone group, P=0.02). No
differences were observed in the subgroup of infants
with signs of airflow limitation during infection (total
days, 569/9752 (5.8%) in the placebo group v 599/
10116 (5.9%) in the beclometasone group, P=0.96).
The proportion of infants with wheeze, with cough,
and using airway drugs did not differ between the
placebo and beclometasone groups during follow-up
(wheeze 62% v 61%, cough 86% v 83%, use of
bronchodilators 42% v 40%, use of steroids 26% v
Table 1 |Baseline characteristics of infants with respiratory syncytial virus infection randomly
assigned to receive extra fine hydrofluoroalkane beclometasone or placebo. Values are
percentages unless stated otherwise
Characteristics
Beclometasone group
(n=119)
Placebo group
(n=124)
Male 52 52
White 85 84
Median (interquartile range) duration of illness
before admission to hospital (days)
3 (1-4) 2 (1-4)
Median(interquartilerange)ageatadmissionto
hospital (months)
2 (1-4) 2 (1-5)
Admitted to intensive care unit, needing
mechanical ventilation
99
Median (interquartile range) gestational age
(weeks)
39.5 (37.5-40.6) 39.5 (37.5-40.6)
Breast fed for at least one month 66 58
Signs of airflow limitation during initial
respiratory tract infection
60 51
Maternal smoking before birth 18 10
Median (interquartile range) atopy score* 1 (0-3) 1 (0-3)
*Semiquantitative parental score for atopy. One point added to score for presence of each atopic symptom
(eczema, hay fever, bronchitis, asthma, and food allergy).
27
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predefined subgroups.
Secondary outcomes and adverse events
The median duration of hospital stay was similar in
bothgroups(4days(interquartilerange3-8days)inthe
placebo group v 5 (4-8) days in the beclometasone
group, P=0.07). The TNO-AZL preschool children
quality of life questionnaire, completed during the
winterseasononeyearafteradmissiontohospital,was
returned by 191 parents (79%). Comparison of the
domain scores for stomach problems, skin problems,
lung problems, sleeping, appetite, liveliness, positive
mood,problembehaviour,anxiety,socialfunctioning,
motor functioning, and communication showed that
infants in the beclometasone group had lower scores
for appetite than infants in the placebo group (median
score 67 (intequartile range 50-100) v 83 (50-100),
P=0.03). At the end of the study, weight did not differ
between the groups.
Measurement of airways resistance during the
summer season in 2 year olds was successfully carried
out in 91 of 163 children (56%). No differences were
found in percentage of successful measurements,
baseline interrupter resistance, and interrupter resis-
tance after inhalation of salbutamol between the two
treatmentgroups(meanbaselineinterrupterresistance
1.15 kPA/L/s (95% confidence interval 1.10 to 1.19
kPA/L/s)inthe placebogroupv1.10kPA/L/s(1.03to
1.17) in the beclometasone group, P=0.9).
Nosevereadverseeventswerereported.Twoinfants
in the beclometasone group had treatment stopped
prematurely because of repeated thrush during the
intervention period; however, the number of infants
with thrush was similar in both groups (41/124 in the
placebo group v 47/119 in the beclometasone group,
odds ratio 1.3 (95% confidence interval 0.8 to 2.2),
P=0.3). Height at age 2 was similar in both groups
(mean 86.8 cm (95% confidence interval 86.2 to 87.5
cm) in placebo group v mean 86.9 cm (86.2 to 87.7),
P=0.8) in beclometasone group.
DISCUSSION
Early initiated high dose extra fine HFA beclometa-
sone given to infants (<13 months) for three months
after respiratory syncytial virus related lower respira-
tory tract infection did not prevent recurrent wheeze.
Thenumberofdayswithwheezeininfantswhodidnot
require mechanical ventilation during infection
showed a modest reduction from 6.4% to 4.3%; a
relative reduction of 32%. No positive effect of our
intervention on health related quality of life was
observed. We found no evidence of side effects with
the intervention.
Comparison with other studies
No treatment during lower respiratory tract infections
caused by respiratory syncytial virus has been shown
convincinglytohaveabeneficialeffectonthecourseof
acute disease or on long term airways morbidity. A
beneficialeffectofleukotrienereceptorantagonistswas
suggested
28 but could not be replicated in a large
doubleblindstudy.
29Thecurrenttrialwasbasedonthe
hypothesis that early initiated high dose inhaled
glucocorticoids modify the immune response after
respiratory syncytial virus infection resulting in the
reduction of recurrent wheeze. Although studies
suggest that about one quarter of infants admitted to
hospital with bronchiolitis receive corticosteroids,
3031
the efficacy of these agents has not been shown
consistently. Several studies have shown that cortico-
steroids are not effective in the acute treatment of
respiratory syncytial virus infections.
32-35 A rando-
mised controlled trial carried out in a birth cohort at
risk of asthma found no effect of inhaled glucocorti-
coids on the progression of episodic wheeze into
persistent wheeze.
36 In addition, no disease modifying
effect of a two year therapy of inhaled corticosteroids
was observed in a third, treatment-free year in pre-
schoolchildrenathighriskofasthma.
37Thetemporary
effects of inhaled steroids in that study and our study
are similar. The role of inhaled glucocorticoids in the
prevention of recurrent wheeze after respiratory
syncytialvirusinfectionisofparticularinterestbecause
the pathogenesis of such infections is thought to be
distinct from that of other wheezing disorders in
infancy.
38 Episodic high doses of inhaled glucocorti-
coids have been shown to provide a partially effective
strategy in children with episodic wheeze caused by
viruses.
39 Previous studies investigating whether
inhaled glucocorticoids can reduce the occurrence of
recurrent wheeze after respiratory syncytial virus
infection have yielded conflicting data and had major
limitations, including small sample size, low dosage of
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Strengths and limitations of study
The major strength of our study is that high dose
treatment with beclometasone was initiated early,
within24hoursofthediagnosisofrespiratorysyncytial
virus infection. Furthermore, the effect on recurrent
wheeze was specifically evaluated in the group of
infants admitted to hospital because of respiratory
syncytial virus infection. To our knowledge this is the
first randomised controlled trial that was sufficiently
powered to evaluate the effect of early high dose
inhaled glucocorticoids on recurrent wheeze after
respiratory syncytial virus infection.
Some of our findings merit further discussion.
Firstly, the data suggest that inhaled beclometasone
did not prevent or diminish recurrent wheeze after
respiratorysyncytialvirusinfectioninthetotalgroupof
infants.Nodecreaseinthenumberofdayswithwheeze
anda smalldecreasein thenumberofdayswithcough
were observed. Quality of life scores and interrupter
resistance did not differ between the beclometasone
and placebo groups. However, the study might be
confounded because infants with severe disease who
needed mechanical ventilation were analysed along
with infants with more mild disease who did not need
mechanical ventilation. No benefit of inhaled beclo-
metasone was observed in mechanically ventilated
infants. The small number of infants in this subgroup
impedes a conclusion about the effect of inhaled
beclometasone on recurrent wheeze in ventilated
infants. However, we speculate that the delayed start
of treatment prevented a treatment induced
modification of the disease’s course. Furthermore, it
is possible that infants with severe disease did not
respond to inhaled beclometasone as a result of
mechanical injury during supportive care or because
ofenhancedvirusmediatedlungdamageatthetimeof
the initial process. In the major subgroup of infants
(n=221) who did not need mechanical ventilation the
number of days with wheeze fell from 6.4% to 4.3%, a
relative reduction of 32%. The effect of inhaled
beclometasone was most pronounced during the first
six months after treatment. The beneficial effect of
beclometasone that was observed in the short term
might be due to reduced airway reactivity during that
period. No differences in quality of life scores and
interrupter resistance were observed between the two
groups,measuredatatimewhentheseverityofwheeze
was similar in both groups. Because the TNO-AZL
preschool children quality of life questionnaire mea-
sures health related quality of life over the past three
monthsonly,the outcomemighthavebeen differentif
measurements were taken earlier.
Secondly, we found treatment with beclometasone
to be ineffective in infants presenting with signs of
airflow limitation during respiratory syncytial virus
infection,asubgroupreportedtobeatincreasedriskof
developing recurrent wheeze.
24 This finding seems
counterintuitive. The disease modifying effect of
beclometasone on recurrent wheeze after respiratory
syncytial virus infection might be limited to specific
phenotypes. The relevance of the presence of signs of
airflow limitation during such infection to both the
development of recurrent wheeze and the effect of
treatment needs further research.
Thirdly, the results might have been influenced by
inadequate administration of and adherence to the
Table 2 |Total number of days with airway symptoms and use of drugs compared with total log days during follow-up of infants
with respiratory syncytial virus infection allocated to extra fine hydrofluoroalkane beclometasone or placebo
Variables
Beclometasone group Placebo group
P value* Rate ratio Total log days
Total days with
symptoms Total log days
Total days with
symptoms
Total group (n=243):
Wheeze
33 568
1761
36 556
2301 0.31 0.83
Cough 7341 9585 0.03 0.83
Steroid use 2578 3105 0.69 0.90
Bronchodilator use 2066 2749 0.39 0.82
No need for mechanical
ventilation (n=221):
Wheeze
30 405
1315
33 149
2120 0.05 0.68
Cough 6681 8724 0.05 0.83
Steroid use 2055 2916 0.34 0.77
Bronchodilator use 1725 2332 0.39 0.81
Signs of airflow limitation
during respiratory tract
infection (n=133):
Wheeze
19 290
1148
18 465
916 0.41 1.20
Cough 4084 4377 0.37 0.89
Steroid use 1739 1028 0.16 1.62
Bronchodilator use 1252 1152 0.90 1.04
*Poisson regression analyses.
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steps correctly for administering the drugs. Moreover,
a sensitivity analysis for infants whose parents carried
out all steps correctly did not change the results. We
determined parental adherence to the treatment regi-
men in a subset of infants by weighing returned
canisters. Most parents gave the prescribed drug
twice daily during at least nine full weeks of the
prescribed three months.
Fourthly, this study was powered to detect a
difference of 14 days between both treatment arms.
The difference of 14 days with wheeze was arbitrarily
defined and we might have missed a smaller but
important effect. The power was based on mean
differences whereas we finally usedPoisson regression
analysis to study differences in numbers of days with
wheeze, which detects smaller differences as statisti-
cally significant.
Fifthly,nootherresearchgroupexternallyvalidated
the logs kept by the parents. We used the logs in two
groupsandobservedthattheoccurrenceofwheezewas
virtually identical between the groups. This similarity
supportedtheinternalvalidityoftheinformationfrom
the logs. Finally, not all parents returned complete log
dataforthefollow-upperiod,andthustheselectiveloss
of data could have biased the results. However,
complete case analysis gave similar results, the
response rate in this trial was high, and missing data
were equally distributed over both treatment groups.
Conclusions and policy implications
A Cochrane review on inhaled corticosteroids in the
prevention of recurrent wheeze could not provide
strong recommendations because of the small number
of participants and the inability to pool all clinical
outcomes.
16 We found that early initiated high dose
extrafineHFAbeclometasoneininfantsagedlessthan
13monthsduringthefirstthreemonthsafteradmission
to hospital for respiratory syncytial virus infection did
not reduce the severity of recurrent wheeze. Only in
our a priori specified subgroup of non-ventilated
children was a modest and temporary reduction in
days with wheeze found. We therefore conclude that
general use of early initiated high dose extra fine HFA
beclometasone should not be advised in infants
admitted to hospital for respiratory syncytial virus
infections.
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